


**UNITED KINGDOM – OCTOBER 2022**

**Status of Cardiovascular Disease (CVD) and Non-communicable diseases (NCD)**


**Country Demographics**

**World Bank Classification**  
**High income**




Life expectancy at birth (in years):

**MALE 79.79 FEMALE 82.99**




**84.15%**

of population living in **urban** areas




**Premature mortality** due to CVD (death during 30-70 years of age) (% of deaths):

**4%**



**Total mortality** due to CVD (% of deaths):


**male: 30.29%**  
**female: 30.21%**



**↑ male: 40%**  
**↑ female: 45%**

Percentage of adult population with raised total **cholesterol** ( $\geq 5.0$  mmol/L)



Global data: 38.9%



**MALE 17.9%** **FEMALE 14.2%**



**Prevalence of tobacco use age  $\geq 15$**

Global data: 36.1% (male) 6.8% (female)

**16%**



Proportion of **premature CVD mortality** attributable to tobacco (%)


**MALE 17.9%** **FEMALE 12.4%**


Percentage of adult population (age-standardized) with raised **blood pressure** (SBP  $\geq 140$  or DBP)

Global data: 24.1% (male) 20.1% (female)


Percentage of adults (age-standardized estimate) who are insufficiently active (**less than 150 minutes** of moderate intensity physical activity per week, or less than 75 minutes of vigorous-intensity physical activity per week):

**male: 31.5%**  
**female: 40%**




Percentage of adults who are overweight (body mass index (BMI) of 25 kg/m<sup>2</sup> or higher):

**male: 68.6%**  
**female: 58.9%**




Percentage of adolescents (ages 11-17) who are insufficiently active (**less than 60 minutes** of moderate- to vigorous intensity physical activity daily):

**male: 74.7%**  
**female: 85.4%**



Prevalence of diabetes in adults (ages 20-79):

**6.3%**






**UNITED KINGDOM**


**Health System Capacity**



**3**  
Number of physicians (per 10,000 population)



**8.68**  
Number of nurses (per 10,000 population)




**23.4**  
Number of hospital beds (per 10,000 population)

**KEY:** No data  Not in place  In process/ partially implemented  In place 





**Essential Medicines and Interventions**

Following essential medicines generally available in primary care facilities in the public health sector:

- |  |  |
|--|--|
| ACE inhibitors: . . . . .  | Metformin: . . . . .     |
| Aspirin: . . . . .        | Insulin: . . . . .      |
| Beta blockers: . . . . .  | Warfarin: . . . . .     |
| Statins: . . . . .        | Clopidogrel: . . . . .  |


**Clinical Practice and Guidelines**

Locally-relevant (national or subnational level):





- Clinical tool to assess CVD risk: . . . . . 
- CVD prevention (within the last 5 years): . . . . . 
- Treatment of tobacco dependence: . . . . . 
- Detection and management of Atrial Fibrillation: . . . . . 

**Cardiovascular Disease Governance**

**A National strategy or plan that addresses:**

- CVDs and their risk factors specifically: . . . . . 
- NCDs and their risk factors: . . . . . 
- A national tobacco control plan: . . . . . 
- A national multisectoral coordination mechanism for tobacco control: . . . . . 
- A national surveillance system that includes CVDs and their risk factors: . . . . . 
- Legislation that mandates essential CVD medicines at affordable prices: . . . . . 
- Policies that ensure screening of individuals at high risk of CVDs: . . . . . 

**Stakeholder action**

- NGO advocacy for CVD policies and programmes: . . . . . 
- Active involvement of patients' organizations in advocacy for CVD prevention and management: . . . . . 
- Involvement of civil society in the development and implementation of a national CVD prevention and control plan: . . . . . 
- Specific activities by cardiology professional associations aimed at 25% reduction in premature CVD mortality by 2025: . . . . . 
- Hypertension screening by businesses at workplaces: . . . . . 